Sylvia Ojoo

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Prevalence and Risk Factors Associated with Precancerous Cervical Cancer Lesions among HIV-Infected Women in Resource-Limited Settings

Peter Memiah, Wangeci Mbuthia, Grace Wanjiku Kiiru et al. · AIDS Research and Treatment · 2012 · 79 citations · Full text

Medicine, Gynecology, Oncology +17

Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects

D. J. Lewis, Charles F. Gilks, Sylvia Ojoo et al. · AIDS · 1994 · 42 citations

Life Sciences, Immunology, Infectious Diseases +16

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Pharmacy, Infectious Disease Control, Pharmacotherapy +17

Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited Clinics

Anthony Amoroso, Martine Etienne‐Mesubi, Anthony Edozien et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 27 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17